Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — December 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #327

    They are not going to throw one of their top-earners under the bus...

    1 Reply Last reply
    0
    • G Offline
      G Offline
      GeorgeBest
      wrote on sidst redigeret af
      #328

      Thanks E L. What confuse me with 48-60 mg group (91% ORR), if they cut out 60 mg ORR drops, but there is on data on patients only receiving 48 mg? There is a group 12 - 48 mg. Which of cource has lover ORR...

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #329

        Talquetamab may be even more interesting than Teclistamab, because JNJ is first mover in a less crowded market.

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GeorgeBest
          wrote on sidst redigeret af
          #330

          less crowded target.

          1 Reply Last reply
          0
          • M Offline
            M Offline
            Mcjean
            wrote on sidst redigeret af
            #331

            Hvad med forskellighederne i graden af sygdom, hvor mange behandlinger de to grupper havde op til? noget du har research på eller er det for svært at aflæse udfra data?

            1 Reply Last reply
            0
            • G Offline
              G Offline
              GeorgeBest
              wrote on sidst redigeret af
              #332

              Begge grupper er heavily pretreated

              1 Reply Last reply
              0
              • G Offline
                G Offline
                GeorgeBest
                wrote on sidst redigeret af
                #333

                Jeg ikke læst alle fodnoter, det bliver squ meget langhåret

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #334

                  it says that population Includes 3 patients who received 60-mg dose before RP2D was determined. If you look at the charts with tumor changes , it may not actually make that much difference in ORR?

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    GeorgeBest
                    wrote on sidst redigeret af
                    #335

                    Good, but it would have been nice with a group of only 48 mg

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      GeorgeBest
                      wrote on sidst redigeret af
                      #336

                      Haven‘t they decided on the optimal dose for Glofitamab? They call it step up dosing...

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #337

                        the scan of that MCL patient on p13 is with only 24mg; I am not a doctor, but that difference after treatment seems pretty clear to me

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          GeorgeBest
                          wrote on sidst redigeret af
                          #338

                          Yes sure

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #339

                            Just a moment...

                            favicon

                            (www.firstwordpharma.com)

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #340

                              Next steps

                              While the burning question was whether or not the novel targets are better used before or after BCMA, the more practical solution is to simply combine the mechanisms. In fact, Johnson & Johnson is already at work on that front, with a Phase I study exploring the combination of talquetamab and the BCMA bispecific antibody teclistamab.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #341

                                There’s also preclinical data supporting the role of CD38-targeting agents in T-cell expansion, which suggests that front-line therapy Darzelex (daratumumab) could help potentiate the T-cell engaging effect of antibodies like talquetamab. Accordingly, Johnson & Johnson is also evaluating that combination in a Phase I trial- along with various combinations of teclistamab and pomalidomide- which could represent its best opportunity for leapfrogging the BCMA drug class.

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  GeorgeBest
                                  wrote on sidst redigeret af
                                  #342

                                  Tak Sukkeralf. Kombinere T&T må trods alt give ca. 10% til Genmab 😉

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #343

                                    Meget svært pt at gisne om hvorledes MM markedet ser ud 5-10 år ude i fremtiden, men man kan da kun være glad for at Genmabs produkter formentlig vil spille en rolle og at Janssen ikke bare lader stå til !

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #344

                                      En stærk fremtidsvision kunne være hexcd38 i kombi med T&T.

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        Plimsoller
                                        wrote on sidst redigeret af
                                        #345

                                        Godt scenarie 🙂

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          Plimsoller
                                          wrote on sidst redigeret af
                                          #346

                                          Link Preview Image
                                          Henrykt storbank efter lægemøde: Genmabs aktie kan blive 5750 kr værd

                                          Genmab har fremlagt data på en konference i weekenden, der imponerer analytikerne Genmabs investorer har endnu engang grund til at drømme stort, efter at selskabet i weekenden har fremlagt nye data me

                                          favicon

                                          borsen.dk (borsen.dk)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger